Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — Q4 FY23 Earnings Presentation
26 slides from Healthcare Global Enterprises's earnings presentation, May 25, 2023
Slide 1: Exchange filing cover letter
May 25, 2023 The Manager – Listing The Manager – Listing National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, I
Slide 2: Healthcare Global Enterprises Limited Investor Presentation May 2023
HEALTHCARE GLOBAL ENTERPRISES LIMITED IN V E S TO R P R E S E N TAT IO N May 2023
Slide 3: Safe Harbor
SAFE HARBOR This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This p
Slide 4: Q4 & FY23 Financial & Operational Highlights
Q4 & FY23 FINANCIAL & SUBASENI LENKA, CANCER WINNER OPERATIONAL HIGHLIGHTS I am eternally thankful to Dr. Panda and other specialists at HCG Panda Cancer Hospital, as the specialists were able to treat my condition the right way, the first time 3 www. h c g e l . c o m
Slide 5: Clinical Highlights & Recognitions
Clinical Highlights & Recognitions Clinical Highlights ❖ Launch of “CELL SEARCH” circulating Tumor Cell (CTC) TESTING. Cell Search is the first and only system which received FDA approval for the precise enumeration of Circulating tumor Cells in patients' blood for diagnostic purposes - First in Ind
Slide 6: Genomics – Future for Cancer Care
Genomics – Future for Cancer Care* HCG is First in Asia to complete ~105 Clinical runs (1000+patients) of Comprehensive Genomic Profiling (CGP) Patient samples Total number of genomic Number of RNA 1,000+ processed with TSO500 1291+ alterations detected in cohort 54 alterations detected in cohort Up
Slide 7: Financial Highlights Q4 FY23
Financial Highlights Q4 FY23 REVENUE R E V E N U E - H C G C e n t e r s (1) REVENUE - Milann Centers^ +21% +22% 0% 4,417 4,259 158 158 3,646 3,488 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 ADJUSTED EBITDA P R O F I T A F T E R TA X 2 P R O F I T A F T E R TA X 2 ADJUSTED EBITDA MARGIN (Pre-IND AS)
Slide 8: Financial Highlights FY23
Financial Highlights FY23 REVENUE R E V E N U E - H C G C e n t e r s (1) REVENUE - Milann Centers^ +21% +22% +7% 16,944 16,281 621 663 13,978 13,357 FY22 FY23 FY22 FY23 FY22 FY23 ADJUSTED EBITDA P R O F I T A F T E R TA X 2 P R O F I T A F T E R TA X 2 ADJUSTED EBITDA MARGIN (Pre-IND AS) ( Po s t -
Slide 9: Improved Performance Leading to Profitability
Improved Performance Leading to Profitability 2.2x 4,081 4,200 4,247 4,417 3,231 3,520 3,581 3,646 Revenue 2,479 2,740 2,981 (INR mn) 1,935 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 3.9x 300 722 747 755 763 EBITDA 194 617 619 633 512 (INR mn) 378 394 Q1'21 Q2'21 Q3'21 Q
Slide 10: Growth Across HCG Centers
Growth Across HCG Centers Matured Centers Emerging Centers^ ~1.4x g r o w t h i n l a s t 9 q u a r t e r s ~2.0x g r o w t h i n l a s t 9 q u a r t e r s +19% +32% REVENUE# 3,090 3,065 3,169 1,090 2,979 1,015 2,596 2,628 2,663 929 945 2,304 2,418 785 826 693 750 535 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4F
Slide 11: Strong Operating Metrics with Significant Capacity Headroom
Strong Operating Metrics with Significant Capacity Headroom Key Driver Metric Indicator % Revenue Q4’22 Q4’23 FY’22 FY’23 18% 80 Lead indicator of Volume Growth; key 11% 68 # New operating metric tracked by HCG; has 21%(1) 20 Registrations (‘000) correlation to out-patient revenue 18 28% 133 Key ind
Slide 12: HCG – Q4FY23 Operational Metrics
HCG – Q4FY23 Operational Metrics # M AT U R E D C E N T E R S EMERGING CENTERS M AT U R E D C E N T E R S TO TA L A O R ( % ) AOR (%) A O R ^* ( % ) ROCE (%) 65.1% 64.8% 65.7% 22.9% 59.9% in Q4FY22 59.1% in Q4FY22 52.9% in Q4FY22 18.7% in Q4FY22 516 bps 572 bps 1,281 bps 420 bps ROCE pre-corporate a
Slide 13: HCG – FY23 Operational Metrics
HCG – FY23 Operational Metrics # M AT U R E D C E N T E R S EMERGING CENTERS M AT U R E D C E N T E R S TO TA L A O R ( % ) AOR (%) A O R ^* ( % ) ROCE (%) 65.4% 64.3% 68.5% 22.0% 58.2% in FY22 58.8% in FY22 54.2% in FY22 16.3% in FY22 726 bps 550 bps 1,429 bps 570 bps ROCE pre-corporate a l l o ca
Slide 14: HCG – Cluster Wise Revenue Break Up
HCG – Cluster Wise Revenue Break Up # C LU ST E R Q4FY23 Q4FY22 Y-o-Y FY23 FY22 Y-o-Y K A R N ATA K A 1,498 1,262 19% 5,692 4,748 20% G U J A R AT 1,084 913 19% 4,163 3,518 18% MAHARASHTRA* 627 529 19% 2,408 2,275 6% EAST INDIA 479 301 59% 1,688 1,168 44% ANDHRA PRADESH 289 281 3% 1,204 1,047 15% TA
Slide 15: Milann – Implementing Strategic Initiatives
Milann – Implementing Strategic Initiatives BENGALURU (5 Centers) Growth Growth Particulars Q4FY23 Q4FY22* FY23 FY22* Y-o-Y Y-o-Y New 1,286 1,651 -22.1% 5,265 4,633 13.6% M S Ramaiah Nagar Registrations Shivananda IVF Cycles 461 497 -7.2% 1,936 1,747 10.8% Indiranagar Revenues Whitefield 158 158 0.2
Slide 16: Capital Expenditure & Net Debt
Capital Expenditure & Net Debt C A P I TA L E X P E N D I T U R E ( R s . M n . ) NET DEBT (Rs. Mn.) NET DEBT 31 st March 2023 31 st Mar 2022 HCG CENTERS FY23 FY22 Bank Debt (1) 3,733 3,543 Vendor Finance (2) 223 333 Matured Centers 1,093.7 458.4 Other Debt 8 34 Emerging Centers 163.3 245.8 Less: Ca
Slide 17: Platform for Attractive Returns with Efficient Capital Allocation and Asset Light Expansion
Platform for Attractive Returns with Efficient Capital Allocation and Asset Light Expansion Capital efficient ROCE growth driven by breakup from Cancer Centers expansion in clinical 18-20% Vintage trials and diagnostics Pre-Corp. Post-Corp. Matured Ongoing value Centers 25.6% 22.1% creation projects
Slide 18: Q4 & FY23 Consolidated Profit & Loss Account
Q4 & FY23 Consolidated Profit & Loss Account Profit and Loss (in Rs. Mn.) Q4 FY23 Q4 FY22 Y-o-Y Q3 FY23 Q-o-Q FY23 FY22 Y-o-Y Revenues from Operations 4,410 3,639 4,239 16,914 13,948 Income from Govt. Grant 7 7 8 30 30 Total Revenue from Operations 4,417 3,646 21% 4,247 4% 16,944 13,978 21% Cost of
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet B alan ce Sh eet - Eq u ity & Liab ili t ie s (in Rs. M n .) M ar -23 M ar -22 Balance Sheet - Assets (Rs. Mn.) Mar -23 Mar -22 E q u ity Sh are Cap ital 1,391 1,390 Non -Cu rren t Assets Oth er E q u ity 7,214 7,313 Prop erty, Plan t An d E q u ip men t 9,718 9,315 Equity
Slide 20: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Cash Flow Statement (in Rs. Mn) Mar-23 Mar-22 Net Profit Before Tax 449 878 Adjustments For: Non - Cash Items / Other Investment Or Financial Items 2,753 1,666 Operating Profit Before Working Capital Changes 3,201 2,543 Changes In Working Capital -459 -105 Cash Gener
Slide 21: Historical Financial Highlights
HISTORICAL FINANCIAL SHANKAR, CANCER WINNER HIGHLIGHTS The days I was at HCG, I felt like I was sleeping at home. They never stop caring for you. The doctors and nurses are always finding ways to make this difficult journey as comfortable as possible 20 www. h c g e l . c o m
Slide 22: Historical Profit & Loss Account
Historical Profit & Loss Account Profit and Loss (in Rs. Mn.) FY23 FY22 FY21 FY20 FY19 CAGR Revenues from Operations 16,914 13,948 10,092 10,923 9,760 Income from Govt. Grant 30 30 43 33 27 Total Revenue from Operations 16,944 13,978 10,134 10,956 9,787 15% Costs of Goods Sold 4,241 3,549 3,632 3,64
Slide 23: Historical Balance Sheet
Historical Balance Sheet Balance Sheet - Equity & Liabilities (in Rs. Mn.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 1,391 1,390 1,254 887 879 Other Equity 7,214 7,313 5,718 2,926 3,933 Equity Attributable To Equity Holders Of The Company 8,605 8,703 6,972 3,813 4,811 Non-Controlling I
Slide 24: Historical Balance Sheet
Historical Balance Sheet Balance Sheet - Assets (in Rs. Mn.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, Plant And Equipment 9,718 9,315 8,531 9,271 8,026 Capital Work in Progress 182 217 300 461 1,440 Rights-of-use Assets 3,813 4,045 4,114 5,776 0 Goodwill 1,812 1,813 963 1,093
Slide 25: Historical Cash Flow Statement
Historical Cash Flow Statement Cash Flow Statement (in Rs. Mn) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Net Profit Before Tax 449 878 -2,287 -1,193 -334 Adjustments For: Non - Cash Items / Other Investment Or Financial 2,753 1,666 3,619 2,988 2,463 Items Operating Profit Before Working Capital Changes 3,2
Slide 26: Thank You
THANK YOU Company: HealthCare Global Enterprises Limited Investor Relation Advisors: Strategic Growth Advisors CIN: L15200KA1998PLC023489 CIN: U74140MH2010PTC204285 For updates and specific queries, please visit Mr. Sagar Shroff / Mr. Ayush Haria www.hcgoncology.com sagar.shroff@sgapl.net / ayush.ha
HealthCare Global Enterprises — Q4 FY23 Earnings Presentation on 6ix